论文部分内容阅读
Objective:To evaluate the efficacy and safety of zoledronic acid for the pain caused by metastatic tumor of bone.Methods:52 patients with metastatic tumor of bone were randomly divided into two groups.The zoledronic acid group received 4 mg zoledronic acid infusion for 30 minutes and the control group received 90 mg pamidronate infusion for 6 hours. Results:The effective rates in zoledronic acid group and control group were 73.08%and 69.23%respectively.No significant difference was observed between the two groups.The median pain relief onset at days 5 and 7,respectively,and no significant difference was observed.The ECOG scores on the 7th day after medication:the differences in the zoledronic acid group before and after medication and between the two groups were both significant(P<0.001 and P=0.0448).The adverse reac- tion was no significant difference between the two groups.Conclusion:Zoledronic acid is efficient and safe in the treatment of pain caused by metastatic tumor of bone and it has low adverse reaction rate and convenient shorter using time.
Objective: To evaluate the efficacy and safety of zoledronic acid for the pain caused by metastatic tumor of bone. Methods: 52 patients with metastatic tumor of bone were differentiated into two groups. Zoledronic acid group received 4 mg zoledronic acid infusion for 30 minutes and the control group received 90 mg pamidronate infusion for 6 hours. Results: The effective rates in zoledronic acid group and control group were 73.08% and 69.23% respectively. Significant difference was observed between the two groups. median pain relief at at days 5 and 7, respectively, and no significant difference was observed. ECOG scores on the 7th day after medication: the differences in the zoledronic acid group before and after medication and between the two groups were both significant (P <0.001 and P = 0.0448 ). The adverse re-tion was no significant difference between the two groups. Confc: Zoledronic acid is efficient and safe in the treatment of pain caused by metastatic tumor of bone and it has low adverse reaction rate and convenient shorter using time.